Ikena Oncology, Inc.
IKNA
$1.12
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -32.82% | -27.71% | |||
| Gross Profit | 32.82% | 27.71% | |||
| SG&A Expenses | 58.99% | -10.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.00% | -23.41% | |||
| Operating Income | -5.00% | 23.41% | |||
| Income Before Tax | 11.28% | 25.20% | |||
| Income Tax Expenses | 430.00% | -83.87% | |||
| Earnings from Continuing Operations | 10.85% | 25.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.85% | 25.46% | |||
| EBIT | -5.00% | 23.41% | |||
| EBITDA | -5.05% | 23.54% | |||
| EPS Basic | 10.84% | 25.45% | |||
| Normalized Basic EPS | 7.22% | 27.53% | |||
| EPS Diluted | 10.84% | 25.45% | |||
| Normalized Diluted EPS | 7.22% | 27.53% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||